Drug
131I-TM-601
131I-TM-601 is a pharmaceutical drug with 4 clinical trials. Historical success rate of 50.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
50.0%
Based on 1 completed trials
Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(25%)
Phase Distribution
Ph phase_2
1
25%
Ph phase_1
3
75%
Phase Distribution
3
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
3(75.0%)
Phase 2Efficacy & side effects
1(25.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
50.0%
1 of 2 finished
Non-Completion Rate
50.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(1)
Terminated(1)
Other(2)
Detailed Status
unknown2
Completed1
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
50.0%
Most Advanced
Phase 2
Trials by Phase
Phase 13 (75.0%)
Phase 21 (25.0%)
Trials by Status
completed125%
unknown250%
terminated125%
Recent Activity
0 active trials
Showing 4 of 4
unknownphase_1
A Study of 131I-TM601 in Adults With Recurrent Malignant Glioma
NCT00683761
terminatedphase_1
A Safety and Efficacy Study of Intravenous 131I-TM601 in Adult Patients With Malignant Melanoma
NCT00733798
unknownphase_2
131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma
NCT00114309
completedphase_1
Safety and Tolerability Study of 131I-TM-601 to Treat Adult Patients With Recurrent Glioma.
NCT00040573
Clinical Trials (4)
Showing 4 of 4 trials
NCT00683761Phase 1
A Study of 131I-TM601 in Adults With Recurrent Malignant Glioma
NCT00733798Phase 1
A Safety and Efficacy Study of Intravenous 131I-TM601 in Adult Patients With Malignant Melanoma
NCT00114309Phase 2
131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma
NCT00040573Phase 1
Safety and Tolerability Study of 131I-TM-601 to Treat Adult Patients With Recurrent Glioma.
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4